PEAK pharmaceutical group Medicines Australia has raised major concerns about the Interim Report from the Review of Pharmacy Remuneration and Regulation (PD Fri), with ceo Milton Catelin saying some of the ideas suggested are ineffective, could diminish medicine quality or lead to potential shortages.
Issues include an option to reduce competition for off-patent medicines by tendering for a maximum of five suppliers per drug; changes to chemotherapy compounding payments that would allow non-TGA approved premises to offer chemotherapy compounding; and possible changes to the Community Service Obligation for wholesalers.
Catelin said Australian pharmacists already deliver world-class healthcare and "any reforms to how medicines are supplied to patients must maintain this standard".
The above article was sent to subscribers in Pharmacy Daily's issue from 26 Jun 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Jun 17
